Water Street Healthcare Partners’ Post

Looking forward for an insightful discussion and knowledge sharing with other esteemed industry experts from pharma industry

Discover how Ingenious e-Brain’s strategic insights enabled a pharmaceutical company to effectively position Drug X for optimal pricing and acceptance in the competitive oncology market. Our evidence-based approach guided the client through complex pricing strategies, ensuring the successful navigation of payer expectations.   Read the detailed case study to explore further: https://lnkd.in/dfFmCE_U #pharmastrategy #oncologymarket #drugpricing #payerstrategy #pharmaceuticals #marketaccess #evidencebased #healthcareconsulting #pricingstrategy #pharmacasestudy #futureproofingbusinesses

From suprachoroidal injectors and sustained release implants to systemic drugs and eye drops for retinal disorders, the Ophthalmic Drug Delivery meeting has all bases covered for you and your team. For more information on how you can get involved and revolutionize your longer lasting and less invasive retinal drug delivery mechanisms! #ophthalmology #retina #retinaldelivery #suprachoroidal #subretinal #sustainedrelease

If you keep up with pharmaceutical news, then you’ll know about the bad news for those suffering from ALS… Amylyx Pharmaceuticals has been hard at work attempting to refine its drug, Relyvrio, which was poised to be a significant breakthrough in the treatment of ALS. However, after some impressive early trial results that suggested a potential to slow disease progression, the drug’s journey took an unexpected turn after the latest round of trials when it failed to meet its primary and secondary endpoints. These events have not only impacted Amylx’s market standing, as it experienced a significant drop in share value but also resonated deeply with the ALS community, which had placed high hopes on Relyvrio. If you’d like to hear more about this story, you can click on the link below to read the article I’ve written about it. https://lnkd.in/d3Sx9T6X #CXAdvisory #CX #CXInsights #Personalization

💥AbbVie acquired Landos Biopharma in a deal announced on March 25, 2024. The acquisition bolsters AbbVie's presence in the autoimmune and inflammatory diseases space. 🌞Focus: Landos is a clinical-stage biopharmaceutical company developing novel oral therapies for autoimmune diseases. 🌞Key Asset: AbbVie gains access to Landos' lead drug candidate, NX-13, a first-in-class treatment for ulcerative colitis. 🌞Deal Value: AbbVie agreed to pay $20.42 per share for Landos, amounting to roughly $137.5 million upfront. Additionally, there's a potential milestone-based payment of up to $75 million. Overall, this acquisition strengthens AbbVie's portfolio in a key therapeutic area and brings a promising drug candidate for ulcerative colitis under their wing. #AbbVie #Landos #Acquisition #BioPharma #Healthcare #LifeSciences #MedicalTechnology #Pharmaceuticals #inflammatory

In Low and Middle Income Countries (LMICs), the challenge isn't just affordability but also the availability of safe, high-quality, and efficacious life-saving pharmaceutical products. Access to these products remains a significant issue, particularly in oncology. My question to industry experts and policymakers: What steps can we take to address this challenge?

Ever wondered how to navigate the complex landscape of advisors, consultants, collaborators, and partners in the pharmaceutical industry? Sharon Cunningham, CEO and Founder of Shorla Oncology shares invaluable insights on successful partnerships and collaborations. "Spending time really understanding if the potential partner shares your values as a company and ensuring that there's chemistry there from the beginning because otherwise, it's not going to work." That's where EVERSANA COMPLETE Commercialization shines! We not only bring expertise and industry knowledge but also prioritize the chemistry and alignment of values with our partners. Learn more: https://ow.ly/cGxh50QFks2 #CommercializationSuccess #COMPLETECommercialization #EVERSANAPartnership

The global dry eye disease market is expected to reach $8884.34 million by 2032, growing at a CAGR of 5.11% during the forecast period, 2023-2032. The introduction of novel diagnostic techniques for dry eye disease plays an essential role in bolstering market growth. Some of the major players operating in the global dry eye disease market are Bausch Health Companies, Allergan Plc (Acquired by AbbVie), Otsuka Pharmaceutical Co Ltd, and others. Request a FREE sample here: https://lnkd.in/dsZkJNV8 . . . AFT Pharmaceuticals Alcon OASIS Medical Otsuka Pharmaceutical Co., Ltd. #dryeyedisease #dryeyes #healthcare #medicaldevices #diagnostics #eyedrops #didyouknow #marketresearch #inkwoodresearch

Looking forward to our Deep Dive at the health.tech conference in Munich together with Luisa Wasilewski, Jonas Albert and Sebastian Cornelius Retter: 🔈 Beyond the Pill is Dead, Long Live DTx Plus Pill! The New Generation of DTx and Pharma-Cooperations – DiGA and Beyond 📃 This session will explore and discuss three specific use cases, far off the beaten path of what is usually mentioned when it comes to the interplay of digital health and pharmaceutical products. The use cases will feature (1) digital therapeutics of higher risk classes (IIb) and their impact on established therapies, (2) Telemonitoring with a combination DiGAs and Drugs as well as options for digital therapeutics outside of the current reimbursement pathways by acting as leverage for the prescription-volume of pharmaceutical products. 📅 Jun 5, 11:15 AM - 12:00 PM regenold GmbH I dtXca I JensonR+ Limited I DigiHealthStart.NRW I Ute Wenning